Efmody® (hydrocortisone modified-release hard capsules)

Efmody® (hydrocortisone modified-release hard capsules), development name Chronocort® is indicated as a treatment for adult and adolescent patients (12 years and older) with the rare condition congenital adrenal hyperplasia (CAH)¹. Efmody was approved by the European Commission in May 2021 for the European Economic Area (including Northern Ireland)(EEA) and by the UK Medicines and Healthcare Products Regulatory Agency (MHRA) in July 2021 for Great Britain (England, Wales and Scotland).

Efmody® is a preparation of hydrocortisone that has been specifically designed to mimic the circadian rhythm of cortisol, when given in a twice-a-day “toothbrush” regimen, (administered last thing at night before sleep and first thing in the morning on waking) to control androgen excess and chronic fatigue in patients with diseases of cortisol deficiency. It is a multi-particulate formulation presented as a capsule and is available in doses of 5mg and 10mg.

1. Efmody Summary of Product Characteristics

Direct Markets